| Document |
Document Title |
|
WO/2024/081864A1 |
The invention relates to compounds and pharmaceutical compositions capable of treating and/or restoring or increasing sensitivity of NT5C2-mutant leukemia cells to chemotherapy, as well as methods of using thereof for treating and/or res...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/066128A1 |
The present invention provides an isoxazoline substituted benzamide compound, and a stereoisomer and an agriculturally or veterinarily acceptable salt thereof. The compound is as shown in formula (I): wherein X represents hydrogen, halog...
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/061665A1 |
The invention relates to isoxazoline compounds of formula I wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for p...
|
|
WO/2024/055801A1 |
The present invention relates to a pyridinamide derivative and a use thereof, and specifically relates to a compound of formula (I) or an isotope labeled compound thereof as a pyridinamide derivative, or an optical isomer, a geometric is...
|
|
WO/2023/227737A9 |
The present invention relates to compounds of Formula (I), (I) or an agronomically acceptable salt of said compounds wherein A1, A2, A3, X1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. The invention further relates to herbicidal...
|
|
WO/2024/046323A1 |
Provided are benzo five-membered nitrogen ring compounds, a preparation method therefor, and the medical uses thereof. Specifically provided are: benzo five-membered nitrogen ring compounds, or pharmaceutically acceptable salts, isomers,...
|
|
WO/2024/039864A1 |
Disclosed are inhibitors of a protein-protein interaction between protein arginine methyltransferase 5 (PRMT5) and methylosome protein 50 (MEP50) based on isoxazolyl methoxyphenyl derivatives. Further disclosed are pharmaceutical composi...
|
|
WO/2024/038036A1 |
The present invention relates to a new process for preparing substituted alkenes of the formula (A), in particular isoxazoline-5,5-vinylcarboxylic acid derivatives of the formula (I).
|
|
WO/2024/028779A1 |
Provided herein are vaporizer formulations comprising fungal material from Amanita muscaria and/or an extract thereof, as well as devices comprising the same. Also provided are methods of using the disclosed formulations and devices to m...
|
|
WO/2024/026359A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
|
|
WO/2024/005548A1 |
The present invention relates to a novel isoxazoline derivative compound and an insecticidal composition comprising same as an active ingredient, wherein the insecticidal composition can exhibit excellent insecticidal effects against var...
|
|
WO/2023/249007A1 |
The present invention provides a calpain inhibitor that has excellent calpain inhibitive capacity. The present invention provides a compound represented by general formula (I), or a salt thereof. (In formula (I), R1 represents a hydrogen...
|
|
WO/2023/247293A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A1, A2, A3, X1, R3, R4, R5, R6 are as defined herein. The invention further relates to herbicidal compositions which...
|
|
WO/2023/244531A1 |
Protein phosphatase 5 (PP5) is a serine/threonine protein phosphatase involved in the maturation and activation of numerous signaling pathways essential for cancer growth. PP5 activity is essential for the survival of clear cell renal ce...
|
|
WO/2023/245150A1 |
The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
|
|
WO/2023/238718A1 |
Provided are: a difluorobutene acid amide compound having an excellent controlling effect against harmful weeds; and an herbicidal composition thereof. The herbicidal composition contains a difluorobutene acid amide compound represented ...
|
|
WO/2023/239853A1 |
Methods of treating cancer, including methods that administer to a patient an agent that may be an inducer of cancer stem cell differentiation and mesenchymal to epithelial transition (MET) in multiple tumor cell lines in a 3D culture mo...
|
|
WO/2023/235384A1 |
Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of enhancing readthrough of genes containing premature termina...
|
|
WO/2023/232560A1 |
The present invention relates to a process for the preparation of a compound of formula (II) wherein M is selected among Na, K and Li, by reacting a compound of formula (I) wherein R1 is selected among hydrogen, Na, K and Li, with a base...
|
|
WO/2023/227676A1 |
The present invention relates to the use of malonic acid monoamides and malonamide esters of the formula (I) wherein the variables are as defined in the claims and the description, for controlling unwanted vegetation, to a method for com...
|
|
WO/2023/225327A1 |
Compounds, compositions, and methods for making and using the compounds for treatment of cancer are provided herein. Mechanistically, these compounds were found to bind to RPS23 and were effective in activating the inducible stress respo...
|
|
WO/2023/221868A1 |
Provided in the present invention are a derivative of an isoxazoline compound and the use thereof in the prevention and treatment of parasitic infections. The derivative of the isoxazoline compound has the following general structural fo...
|
|
WO/2023/221862A1 |
Provided are an anti-parasitic infection external pharmaceutical formulation , a preparation method therefor and use thereof. The external pharmaceutical formulation comprises a first active ingredient and an aldehyde compound, the first...
|
|
WO/2023/222850A1 |
The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
|
|
WO/2023/194496A1 |
A process for the preparation of compound of formula (I) is provided: where R, R1, R2, R3 and R4 are as defined in the description.
|
|
WO/2023/182871A1 |
The present invention relates to a 3-phenylisoxazole derivative, a preparation method therefor, and a pharmaceutical composition for preventing or treating eye disease, containing same as an active ingredient. The 3-phenylisoxazole deriv...
|
|
WO/2023/170025A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compo...
|
|
WO/2023/158602A1 |
Disclosed are compounds of Formula I including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein G, Z, L, J, A and T are as defined in the disclosure. Also disclosed are compositions containing the compound...
|
|
WO/2023/155912A1 |
The present invention provides a recyclable hypervalent iodine reagent having a high reactivity. Specifically, the invention provides a hypervalent iodine reagent capable of realizing high-selectivity coupling, and a method for preparing...
|
|
WO/2023/157862A1 |
Provided is a method for producing α-fluoroether starting from an inactivated chloride. Disclosed is a method for producing a compound represented by formula (3), the method comprising step A in which a compound represented by formula (...
|
|
WO/2023/154466A1 |
Arylbenzoisoxazole compounds of Formula (II), where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcohol...
|
|
WO/2023/152415A1 |
The present invention relates to a compound of formula I, wherein the groups R1 to R5 and Cy have the meaning described in the description, for use thereof in the treatment and/or prevention of an infection or disease caused by the infec...
|
|
WO/2023/115165A1 |
The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
|
|
WO/2023/114824A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/114818A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/114819A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/104616A1 |
The invention relates to a novel method for producing isoxazolinecarboxylic acid derivatives of formula (I).
|
|
WO/2023/104035A1 |
Disclosed are a substituted monocyclic or bicyclic heterocyclic compound, a preparation method therefor and a medical use thereof. Specifically, disclosed are a substituted monocyclic or bicyclic heterocyclic compound having a structure ...
|
|
WO/2023/097809A1 |
The present invention relates to the technical field of fireproof flame-retardant coatings. An antibacterial fireproof coating based on a sulfanilamide-silver chemical compound and a preparation method thereof. The preparation method of ...
|
|
WO/2023/101595A1 |
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and bin...
|
|
WO/2023/099641A1 |
The present invention relates to a new process for producing isoxazoline-5,5-vinylcarboxylic acid derivatives of formula (I).
|
|
WO/2023/092219A1 |
There is provided adjunctive D-cycloserine (DCS) augmentation of transcranial magnetic stimulation (TMS) therapy for Obsessive Compulsive Disorder (OCD). There is also provided combination therapies and therapeutic methods that include i...
|
|
WO/2023/096304A1 |
The present invention relates to an isoxazole derivative or a pharmaceutically acceptable salt thereof and a composition for preventing or treating CSF-1R related diseases comprising the derivative as an active ingredient. The isoxazole ...
|
|
WO/2023/090859A1 |
The present invention relates to: a novel method for preparing an isoxazole derivative, which is useful as a farnesoid X receptor (FXR, NR1H4) agonist; a novel intermediate used in the preparation method; and a method for preparing the p...
|
|
WO/2023/090858A1 |
The present invention relates to: a novel method for preparing an isoxazole derivative that is useful as an agonist for a farnesoid X receptor (FXR, NR1H4) and an intermediate for preparing the agonist; and a method for preparing an inte...
|
|
WO/2023/072671A1 |
The present invention relates to the use of strobilurin type compounds of formula I and the N- oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b...
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/073115A1 |
The present invention relates to the use of the compound of the formula (I) and the composition thereof as control agent for plant diseases caused by fungi, oomycetes and bacteria. Plant pathogens produce self-aggregating proteins, like ...
|
